vs

Side-by-side financial comparison of KITE REALTY GROUP TRUST (KRG) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $200.7M, roughly 1.0× KITE REALTY GROUP TRUST). KITE REALTY GROUP TRUST runs the higher net margin — 0.2% vs -62.0%, a 62.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -9.2%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -2.8%).

Kite Realty Group Trust is a publicly traded U.S.-headquartered real estate investment trust. It primarily owns, operates, and develops high-quality open-air shopping centers and mixed-use properties, with a portfolio spanning key regional markets across the United States. Its tenant base includes national retail chains, local independent merchants, and dining and entertainment operators, serving local community consumer needs.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

KRG vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.0× larger
RARE
$207.3M
$200.7M
KRG
Growing faster (revenue YoY)
RARE
RARE
+35.1% gap
RARE
25.9%
-9.2%
KRG
Higher net margin
KRG
KRG
62.2% more per $
KRG
0.2%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-2.8%
KRG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
KRG
KRG
RARE
RARE
Revenue
$200.7M
$207.3M
Net Profit
$330.0K
$-128.6M
Gross Margin
Operating Margin
-54.7%
Net Margin
0.2%
-62.0%
Revenue YoY
-9.2%
25.9%
Net Profit YoY
-51.6%
3.5%
EPS (diluted)
$0.06
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRG
KRG
RARE
RARE
Q1 26
$200.7M
Q4 25
$204.2M
$207.3M
Q3 25
$205.1M
$159.9M
Q2 25
$213.4M
$166.5M
Q1 25
$221.8M
$139.3M
Q4 24
$214.7M
$164.6M
Q3 24
$207.3M
$139.5M
Q2 24
$212.4M
$147.0M
Net Profit
KRG
KRG
RARE
RARE
Q1 26
$330.0K
Q4 25
$180.8M
$-128.6M
Q3 25
$-16.2M
$-180.4M
Q2 25
$110.3M
$-115.0M
Q1 25
$23.7M
$-151.1M
Q4 24
$21.8M
$-133.2M
Q3 24
$16.7M
$-133.5M
Q2 24
$-48.6M
$-131.6M
Operating Margin
KRG
KRG
RARE
RARE
Q1 26
Q4 25
-54.7%
Q3 25
-106.9%
Q2 25
-64.8%
Q1 25
24.2%
-102.6%
Q4 24
23.0%
-74.3%
Q3 24
21.7%
-94.6%
Q2 24
-10.5%
-79.1%
Net Margin
KRG
KRG
RARE
RARE
Q1 26
0.2%
Q4 25
88.6%
-62.0%
Q3 25
-7.9%
-112.8%
Q2 25
51.7%
-69.0%
Q1 25
10.7%
-108.5%
Q4 24
10.2%
-80.9%
Q3 24
8.1%
-95.7%
Q2 24
-22.9%
-89.5%
EPS (diluted)
KRG
KRG
RARE
RARE
Q1 26
$0.06
Q4 25
$0.83
$-1.28
Q3 25
$-0.07
$-1.81
Q2 25
$0.50
$-1.17
Q1 25
$0.11
$-1.57
Q4 24
$0.10
$-1.34
Q3 24
$0.08
$-1.40
Q2 24
$-0.22
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRG
KRG
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$32.5M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.9B
$-80.0M
Total Assets
$6.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRG
KRG
RARE
RARE
Q1 26
$32.5M
Q4 25
$36.8M
$421.0M
Q3 25
$68.7M
$202.5M
Q2 25
$182.0M
$176.3M
Q1 25
$49.1M
$127.1M
Q4 24
$478.1M
$174.0M
Q3 24
$467.5M
$150.6M
Q2 24
$273.8M
$480.7M
Total Debt
KRG
KRG
RARE
RARE
Q1 26
Q4 25
$3.0B
Q3 25
$2.9B
Q2 25
$3.0B
Q1 25
$2.9B
Q4 24
$3.2B
Q3 24
$3.2B
Q2 24
$3.0B
Stockholders' Equity
KRG
KRG
RARE
RARE
Q1 26
$2.9B
Q4 25
$3.1B
$-80.0M
Q3 25
$3.2B
$9.2M
Q2 25
$3.3B
$151.3M
Q1 25
$3.3B
$144.2M
Q4 24
$3.3B
$255.0M
Q3 24
$3.3B
$346.8M
Q2 24
$3.4B
$432.4M
Total Assets
KRG
KRG
RARE
RARE
Q1 26
$6.4B
Q4 25
$6.7B
$1.5B
Q3 25
$6.6B
$1.2B
Q2 25
$6.9B
$1.3B
Q1 25
$6.7B
$1.3B
Q4 24
$7.1B
$1.5B
Q3 24
$7.1B
$1.5B
Q2 24
$7.0B
$1.6B
Debt / Equity
KRG
KRG
RARE
RARE
Q1 26
Q4 25
0.98×
Q3 25
0.93×
Q2 25
0.91×
Q1 25
0.89×
Q4 24
0.97×
Q3 24
0.97×
Q2 24
0.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRG
KRG
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
3.3%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRG
KRG
RARE
RARE
Q1 26
Q4 25
$106.6M
$-99.8M
Q3 25
$116.2M
$-91.4M
Q2 25
$132.8M
$-108.3M
Q1 25
$74.1M
$-166.5M
Q4 24
$111.0M
$-79.3M
Q3 24
$112.4M
$-67.0M
Q2 24
$142.1M
$-77.0M
Free Cash Flow
KRG
KRG
RARE
RARE
Q1 26
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
FCF Margin
KRG
KRG
RARE
RARE
Q1 26
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Capex Intensity
KRG
KRG
RARE
RARE
Q1 26
3.3%
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Cash Conversion
KRG
KRG
RARE
RARE
Q1 26
Q4 25
0.59×
Q3 25
Q2 25
1.20×
Q1 25
3.12×
Q4 24
5.09×
Q3 24
6.72×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KRG
KRG

Rental income$198.0M99%
Fee income$1.3M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons